Russell L. Margolis, MD/PhD

Psychiatry and Behavioral Sciences Johns Hopkins University, Baltimore, MD 
"Russell Margolis"

1982 A.B. Princeton University
1986 M.D. Johns Hopkins University School of Medicine
1986-1987 Medicine-Psychiatry Internship, Francis Scott Key Hospital
1987-1990 Psychiatry Residency, Johns Hopkins
1990-1992 Neurobiology Fellowship, National Institute of Mental Health
1990-1992 Government Service, Public Health Service
since 1992 Johns Hopkins University

Mean distance: 18.84 (cluster 31)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Li PP, Sun X, Xia G, et al. (2016) ATXN2-AS, a gene antisense to ATXN2, is associated with SCA2 and ALS. Annals of Neurology
Frank S, Testa CM, et al. (2016) Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. Jama. 316: 40-50
Brandt AS, Unschuld PG, Pradhan S, et al. (2016) Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7Tesla. Schizophrenia Research
Bañez-Coronel M, Ayhan F, Tarabochia AD, et al. (2015) RAN Translation in Huntington Disease. Neuron. 88: 667-77
O'Hearn EE, Hwang HS, Holmes SE, et al. (2015) Neuropathology and Cellular Pathogenesis of Spinocerebellar Ataxia Type 12. Movement Disorders : Official Journal of the Movement Disorder Society
Sun X, Li PP, Zhu S, et al. (2015) Nuclear retention of full-length HTT RNA is mediated by splicing factors MBNL1 and U2AF65. Scientific Reports. 5: 12521
Krause A, Mitchell C, Essop F, et al. (2015) Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics
Angus D, Herd C, Stone C, et al. (2015) Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial The Lancet Neurology. 14: 39-47
Wen Z, Nguyen HN, Guo Z, et al. (2014) Synaptic dysregulation in a human iPS cell model of mental disorders. Nature. 515: 414-8
Margolis RL. (2014) Tetrabenazine, depression and suicide: good news. Journal of Huntington's Disease. 3: 137-8
See more...